drugset / Trial / NCT00041496

Prevention Of Recurrence Of Atrial Fibrillation

NCT00041496 ↗

Phase 2 Completed 520 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of this study is to determine whether the study drug is effective in preventing the recurrence of atrial fibrillation (an abnormal heart rhythm).

Timeline

Start
2001-11
Primary completion
2003-12
Completion
2003-12

Drugs

EvaluationDrugModalityDoseRoute
Subject SB-207266 Unknown 10 mg —
Subject SB-207266 Unknown 25 mg —
Subject SB-207266 Unknown 40 mg —

Indications